GILD and ABBV will respectfully share the market under the graces of those cutting the checks.
There are lots of checks to cut. NOT cutting the checks for these near-cure drugs for HCV will mean cutting other checks for direct costs and comorbidities.
EVEN at $84,000 the savings to the health care system will be substantial over the life of the patient. As I recall the annual cost of an HCV patient runs from $7K to $42K annually as the disease progresses.
Market Data 
Markets 
AI
